A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer NIAGARA

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03732677

Study #:
STUDY00143805

Start Date:
Aug 07, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03732677

View Complete Trial Details & Eligibility at ClinicalTrials.gov